New crystallized lithium aims to improve bipolar treatment

NCT ID NCT07540338

Recruiting now Disease control Sponsor: Alzamend Neuro, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 29, 2026 · Updated 3 times

Summary

This study compares a new crystallized lithium (AL001) to standard lithium carbonate in 20 people with bipolar I disorder. Participants take each drug for 14 days and undergo MRIs and blood tests to measure how lithium enters the brain and body. The goal is to see if AL001 is safer and works better at reaching the brain.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AL001 (crystallized lithium) and lithium carbonate
What this could lead to: If successful, AL001 could offer a safer or more effective way to manage bipolar I disorder by delivering lithium more efficiently to the brain.
What could go wrong: This is a small, early-phase study with only 20 participants, so results may not apply broadly. Lithium can cause side effects like kidney or thyroid issues, and the new form may not prove better.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BIPOLAR I DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bipolar I disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BIPOLAR I DISORDER

Contacts and locations

Locations

Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.